United States-based Amgen (NASDAQ: AMGN) yesterday reported its financial results for the second quarter of 2019.
The company reported total revenues of USD5.9bn in the second quarter of 2019, down 3% compared to the second quarter of 2018.
The firm posted USD1.3bn of free cash flow in the second quarter of 2019 compared with USD1.9bn in the year-ago period. GAAP earnings per share (EPS) increased 3% to USD3.57 benefited by lower weighted-average shares outstanding.
Robert A Bradway, chairman and chief executive officer, said, 'With our newer products generating strong volume gains globally and many first-in-class medicines advancing through our pipeline, we are well positioned to serve patients and deliver long-term growth for our shareholders.'
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development